Verition Fund Management’s Terns Pharmaceuticals TERN Stock Holding History

Verition Fund Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.3M	Buy	802,293 +789,528	+6,185%	+$32.4M	0.27%	53
2025 Q4	$516K	Buy	+12,765	New	+$295K	﹤0.01%	2633
2025 Q1	–	Sell	-19,350	Closed	-$107K	–	3708
2024 Q4	$107K	Buy	+19,350	New	+$131K	﹤0.01%	3076
2023 Q3	–	Sell	-20,500	Closed	-$179K	–	2678
2023 Q2	$179K	Sell	20,500 -5,090	-20%	-$59.3K	﹤0.01%	1883
2023 Q1	$303K	Buy	+25,590	New	+$245K	﹤0.01%	1517

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Verition Fund Management's TERN Position: Q1 2026 in Review

Verition Fund Management increased its Terns Pharmaceuticals (TERN) stake by 6,185% in Q1 2026, buying an estimated $32.4M and bringing the position to 802,293 shares worth $42.3M. The position accounts for 0.27% of the portfolio, ranked #53.

Verition Fund Management first reported a position in TERN in Q1 2023 and has held it in 5 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Verition Fund Management held 802,293 shares of Terns Pharmaceuticals worth $42.3M as of Q1 2026.
Verition Fund Management bought 789,528 Terns Pharmaceuticals shares in Q1 2026, an estimated $32.4M.
Terns Pharmaceuticals made up 0.27% of Verition Fund Management's portfolio in Q1 2026, its #53 holding.
Verition Fund Management first reported a position in Terns Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.